(PI; Karlsruhe Institute of Technology, KIT)
Project(s) involved: Kassel/Di Ventura
Curriculum Vitae Olivier Kassel
Date of birth: 31.03.1968
Nationality French
Marital status: Married, one child
Address: Karlsruhe Institute of Technology
Institute of Toxicology and Genetics
Hermann-von-Helmholtz-Platz 1
76344 Eggenstein-Leopoldshafen
Tel.: 0721 608 23911
Employment
2008-present Group Leader, Institute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Karlsruhe
2004-2008 Project Leader, Institut für Toxikologie und Genetik, Forschungszentrum Karlsruhe
1999-2004 Post-doctorant, Institut für Toxikologie und Genetik, Forschungszentrum Karlsruhe
1995-1998 “Allocataire de Recherche du Ministère de l’Education Nationale, de la Recherche et de la Technologie”, INSERM, U425,
Strasbourg (France)
1993 Research Assistant. Department of Clinical Pharmacology, University of Southampton (UK)
Education
1995-1999 PhD in Molecular and Cellular Pharmacology (Université Louis Pasteur, Strasbourg I)
1994-1995 Postgraduate Degree in Pharmacology and Pharmacochemistry, specialisation in Molecular and Cellular Pharmacology
(Diplôme d'Études Approfondies,
Université Louis Pasteur, Strasbourg I)
1988-1991 Master of Biological and Medical Sciences (Université Louis Pasteur, Strasbourg I).
1986-1992 Pharm. D. (School of Pharmacy, Université Louis Pasteur, Strasbourg I, France).
Scholarships, Fellowships and awards
1994-1995 Postgraduate training scholarship, Université Louis Pasteur, Strasbourg I
1995-1998 Doctoral fellowship, Ministère de l’Education Nationale, de la Recherche et de la Technologie
1999-2000 Post-doctoral fellowship. Institut National de la Santé et de la Recherche Médicale - Deutsche Forschungsgemeinshaft
(INSERM-DFG) exchange programme
2002 Schoeller-Junkmann-Preiss 2002 awarded by the German Endocrine Society for work in the field of
glucocorticoid receptor action
2004 Enrolled in the High Potential Program of the Forschungszentrum Karlsruhe (tenure position)
Selected publications
Chakraborty A, Diefenbacher ME, Mylona A, Kassel O & Behrens A (2015) The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling. Nat Commun 6: 6782
Diefenbacher ME, Reich D, Dahley O, Kemler D, Litfin M, Herrlich P & Kassel O (2014) The LIM Domain Protein nTRIP6 Recruits the Mediator Complex to AP-1-Regulated Promoters. PLoS ONE 9: e97549
Röder IV, Strack S, Reischl M, Dahley O, Khan MM, Kassel O, Zaccolo M & Rudolf R (2012) Participation of Myosin va and pka type I in the regeneration of neuromuscular junctions. PLoS ONE 7: e40860
Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M & Sleeman JP (2012) CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci 69: 435–448
Diefenbacher ME, Litfin M, Herrlich P & Kassel O (2010) The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor. Mol Cell Endocrinol 320: 58–66
Diefenbacher M, Sekula S, Heilbock C, Maier JV, Litfin M, van Dam H, Castellazzi M, Herrlich P & Kassel O (2008) Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol Endocrinol 22: 1767–1780
Kassel O & Herrlich P (2007) Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol 275: 13–29
Kassel O, Schneider S, Heilbock C, Litfin M, Göttlicher M & Herrlich P (2004) A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev 18: 2518–2528
Da Silva CA, Heilbock C, Kassel O & Frossard N (2003) Transcription of stem cell factor (SCF) is potentiated by glucocorticoids and interleukin-1beta through concerted regulation of a GRE-like and an NF-kappaB response element. The FASEB Journal 17: 2334–2336
Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M & Cato AC (2001) Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20: 7108–7116